Upcoming event

FIERCE study

Dr. Arlene Siefker-Radtke on FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.